The primary focus of the Center for AIDS Research at Stanford University is to develop more new human therapeutic antivirals, including both chemical and immunobiologic agents. ln order to more broadly cover major strategies for treatment and prevention of infection and disease, there will be additional efforts on vaccine development within the center as well. Three of the principal members of the center are involved in an NIAID sponsored AIDS Clinical Trial Group and the fourth is involved in studies of pathogenesis of HlV infection as well as directing a NIAID Drug Discovery Program Contract. The clinical trials team will include experts in clinical virology, immunology, pharmacology and trial design. ln order to facilitate greater involvement of our university in the AIDS area, other scientists will also be involved in the center, including molecular biologists interested in the control of replicative mechanisms of this retrovirus, biometricians and economists studying the new treatments, clinicians interested in disease mechanisms, immunologists expert in cellular immunity, and virologists interested in defining HlV replication and critical immune epitopes. ln addition to clinical studies, at least two different murine animal models will be used to examine anti- retroviral action, including an immunosuppressive murine retrovirus as well as HIV virus effects on human lymphoid cells replicating in immunodeficient mice. In order to carry out the intended studies, shared core facilities will be established in virology, immunology and cell separation as well as a university-wide seminar series and a program of local administrated grants. These programs will be used as prime stimuli to support both clinical and fundamental work which furthers the center's primary focus on therapy of HIV infection of man.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027762-05
Application #
3101080
Study Section
Special Emphasis Panel (SRC (41))
Project Start
1988-09-30
Project End
1994-03-31
Budget Start
1993-02-01
Budget End
1994-03-31
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Brennan, Greg; Kitzman, Jacob O; Rothenburg, Stefan et al. (2014) Adaptive gene amplification as an intermediate step in the expansion of virus host range. PLoS Pathog 10:e1004002
Child, Stephanie J; Brennan, Greg; Braggin, Jacquelyn E et al. (2012) Species specificity of protein kinase r antagonism by cytomegalovirus TRS1 genes. J Virol 86:3880-9
McFadden, D C; Tomavo, S; Berry, E A et al. (2000) Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 108:12-Jan
McFadden, D C; Boothroyd, J C (1999) Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii. J Eukaryot Microbiol 46:81S-82S
Katzenstein, D A; Kundu, S; Spritzler, J et al. (1999) Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. J Acquir Immune Defic Syndr 22:341-7
Kundu, S K; Katzenstein, D; Valentine, F T et al. (1997) Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. J Acquir Immune Defic Syndr Hum Retrovirol 15:269-74
Owens, D K; Holodniy, M; Garber, A M et al. (1996) Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med 124:803-15
Shafer, R W; Small, P M; Larkin, C et al. (1995) Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. J Infect Dis 171:170-6
Shafer, R W; Iversen, A K; Winters, M A et al. (1995) Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 172:70-8
Chao, N J; Kastrissios, H; Long, G D et al. (1995) A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 75:1354-9

Showing the most recent 10 out of 45 publications